Blueprint Medicines Backtesting

Blueprint Medicines Corporation -- USA Stock  

USD 100.61  1.88  1.83%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Blueprint Medicines Corporation and determine expected loss or profit from investing in Blueprint Medicines over given investment horizon. Check also Blueprint Medicines Hype Analysis, Blueprint Medicines Correlation, Blueprint Medicines Valuation, Blueprint Medicines Volatility as well as analyze Blueprint Medicines Alpha and Beta and Blueprint Medicines Performance
 Time Horizon     30 Days    Login   to change

Blueprint Medicines 'What if' Analysis

February 19, 2018
No Change 0.00  0.0%
In 31 days
March 21, 2018
If you would invest  0.00  in Blueprint Medicines on February 19, 2018 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corporation or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with NantKwest, DelMar Pharmaceuticals, Dimension Therapeutics, Denali Therapeutics, VBI Vaccines, and Vascular Biogenics. Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that ta...

Blueprint Medicines Upside/Downside Indicators


Blueprint Medicines Market Premium Indicators

Blueprint Medicines lagged returns against current returns

 Current and Lagged Values 

Blueprint Medicines regressed lagged prices vs. current prices

 Current vs Lagged Prices 

Blueprint Medicines Backtested Returns

Macroaxis considers Blueprint Medicines not too volatile given 1 month investment horizon. Blueprint Medicines secures Sharpe Ratio (or Efficiency) of 0.3668 which signifies that Blueprint Medicines had 0.3668% of return per unit of risk over the last 1 month. Our philosophy towards foreseeing volatility of a stock is to use all available market data together with company specific technical indicators that cannot be diversified away. By analyzing Blueprint Medicines technical indicators you can presently evaluate if the expected return of 0.9763% is justified by implied risk. Please makes use of Blueprint Medicines Downside Deviation of 2.06, Risk Adjusted Performance of 0.387 and Mean Deviation of 2.14 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100 Blueprint Medicines holds performance score of 24. The firm shows Beta (market volatility) of 0.0567 which signifies that as returns on market increase, Blueprint Medicines returns are expected to increase less than the market. However during bear market, the loss on holding Blueprint Medicines will be expected to be smaller as well.. Although it is vital to follow to Blueprint Medicines historical returns, it is good to be conservative about what you can actually do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. We have found twenty-one technical indicators for Blueprint Medicines Corporation which you can use to evaluate performance of the firm. Please makes use of Blueprint Medicines Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to make a quick decision on weather Blueprint Medicines price patterns will revert.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation 0.58 

Modest predictability

Blueprint Medicines Corporation has modest predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from February 19, 2018 to March 6, 2018 and March 6, 2018 to March 21, 2018. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Blueprint Medicines price fluctuation can be explain by its past prices.
Correlation Coefficient 0.58
Spearman Rank Test 0.48
Price Variance 2.15
Lagged Price Variance 20.29

Blueprint Medicines Lagged Returns

 Regressed Prices 

Blueprint Medicines Performance vs DOW

The median price of Blueprint Medicines for the period between Mon, Feb 19, 2018 and Wed, Mar 21, 2018 is 99.09 with a coefficient of variation of 6.72. The daily time series for the period is distributed with a sample standard deviation of 6.4, arithmetic mean of 95.18, and mean deviation of 5.6. The Stock received some media coverage during the period.
 Price Growth (%)  
Exercise or conversion by Haviland Kate of 2500 shares of Bl...03/20/2018